• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by CONMED Corporation

    6/16/26 4:30:58 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    cnmd-20260616
    FALSEFALSE00008169560000816956iso4217:USDxbrli:purecnmd:loanxbrli:shares00008169562025-01-012025-12-310000816956cnmd:EBP005Member2025-01-012025-12-310000816956cnmd:EBP005Member2025-12-310000816956cnmd:EBP005Member2024-12-310000816956srt:MinimumMembercnmd:EBP005Member2025-01-012025-12-310000816956srt:MaximumMembercnmd:EBP005Member2025-01-012025-12-310000816956cnmd:EBP005Memberus-gaap:SubsequentEventMember2026-01-012026-01-010000816956us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2025-12-310000816956us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2025-12-310000816956us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2025-12-310000816956us-gaap-ebp:EmployeeBenefitPlanSelfDirectedBrokerageAccountMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2025-12-310000816956us-gaap-ebp:EmployeeBenefitPlanSelfDirectedBrokerageAccountMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2025-12-310000816956us-gaap-ebp:EmployeeBenefitPlanSelfDirectedBrokerageAccountMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2025-12-310000816956us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2025-12-310000816956us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2025-12-310000816956us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2025-12-310000816956us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2025-12-310000816956us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2025-12-310000816956us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2025-12-310000816956us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2025-12-310000816956us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2025-12-310000816956us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2025-12-310000816956cnmd:EBP005Memberus-gaap:FairValueInputsLevel1Member2025-12-310000816956cnmd:EBP005Memberus-gaap:FairValueInputsLevel2Member2025-12-310000816956cnmd:EBP005Memberus-gaap:FairValueInputsLevel12And3Member2025-12-310000816956cnmd:EBP005Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000816956us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2024-12-310000816956us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2024-12-310000816956us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2024-12-310000816956us-gaap-ebp:EmployeeBenefitPlanSelfDirectedBrokerageAccountMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2024-12-310000816956us-gaap-ebp:EmployeeBenefitPlanSelfDirectedBrokerageAccountMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2024-12-310000816956us-gaap-ebp:EmployeeBenefitPlanSelfDirectedBrokerageAccountMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2024-12-310000816956us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2024-12-310000816956us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2024-12-310000816956us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2024-12-310000816956us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2024-12-310000816956us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2024-12-310000816956us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2024-12-310000816956us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel1Membercnmd:EBP005Member2024-12-310000816956us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel2Membercnmd:EBP005Member2024-12-310000816956us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel12And3Membercnmd:EBP005Member2024-12-310000816956cnmd:EBP005Memberus-gaap:FairValueInputsLevel1Member2024-12-310000816956cnmd:EBP005Memberus-gaap:FairValueInputsLevel2Member2024-12-310000816956cnmd:EBP005Memberus-gaap:FairValueInputsLevel12And3Member2024-12-310000816956cnmd:EBP005Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000816956cnmd:EBP005Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000816956cnmd:EBP005Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000816956Fidelity 500 Index Fundcnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2045 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2040 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Contrafund - Class Kcnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2035 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2050 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2030 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2055 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Janus Henderson Enterprise Collective Fund Class IIIcnmd:EBP005Member2025-12-310000816956Participant - Directed Brokerage Link Accountcnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2025 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2060 Fund - Class K6cnmd:EBP005Member2025-12-310000816956John Hancock Disciplined Value Mid Cap Trust Class B5cnmd:EBP005Member2025-12-310000816956Putnam Large Cap Value Trust IAcnmd:EBP005Member2025-12-310000816956Fidelity Government Money Market Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Diversified International Fund - Class Kcnmd:EBP005Member2025-12-310000816956John Hancock Core Plus Fixed Income Trust Class I2cnmd:EBP005Member2025-12-310000816956Fidelity Global ex U.S. Index Fundcnmd:EBP005Member2025-12-310000816956Fidelity Managed Income Portfolio - Class 1cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2020 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity U.S. Bond Index Fundcnmd:EBP005Member2025-12-310000816956Fidelity Extended Market Index Fundcnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2065 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Emerging Markets Fund - Class Kcnmd:EBP005Member2025-12-310000816956Franklin Small Cap Value GG Trust CIT Class Rcnmd:EBP005Member2025-12-310000816956CONMED Corporation Common Stockcnmd:EBP005Member2025-12-310000816956JP Morgan U.S. Small Company Fund Class R6cnmd:EBP005Member2025-12-310000816956PIMCO Income Fund Institutional Classcnmd:EBP005Member2025-12-310000816956Fidelity Freedom Retirement Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2015 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Putnam Stable Value Fundcnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2010 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Fidelity Freedom 2070 Fund - Class K6cnmd:EBP005Member2025-12-310000816956Invesco Discovery Fund Class R6cnmd:EBP005Member2025-12-310000816956Interest Bearing Cash Accountscnmd:EBP005Member2025-12-310000816956srt:MinimumMemberNotes receivable from participantscnmd:EBP005Member2025-01-012025-12-310000816956srt:MaximumMemberNotes receivable from participantscnmd:EBP005Member2025-01-012025-12-310000816956Notes receivable from participantscnmd:EBP005Member2025-12-31

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    WASHINGTON, D.C. 20549
     
    Form 11-K
     
    ý  Annual Report Pursuant To Section 15(d) Of
    The Securities Exchange Act of 1934
    For the fiscal year ended December 31, 2025
     
    OR
     
    ¨  Transition Report Pursuant To Section 15(d) Of
    The Securities Exchange Act of 1934
    For the transition period from ________ to _________
     
    Commission File Number 001-39218
     
    (A) Full title of the plan and the address
    of the plan, if different from that of
    the issuer named below:
     
    CONMED CORPORATION
    Retirement Savings Plan
     
    (B) Name of issuer of the securities held
    pursuant to the plan and the address
    of its principal executive office:
     
    CONMED CORPORATION
    11311 Concept Blvd
    Largo, Florida 33773





    CONMED Corporation
    Retirement Savings Plan
    Index to Financial Statements
    December 31, 2025 and 2024

     Page
      
    Report of Independent Registered Public Accounting Firm
    1
      
    Financial Statements: 
      
    Statements of Net Assets Available for Benefits as of December 31, 2025 and 2024
    2
      
    Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2025
    3
      
    Notes to Financial Statements
    4
      
    Supplemental Schedule: * 
      
    Schedule H, line 4i - Schedule of Assets (Held at End of Year) as of December 31, 2025
    9
    Signatures
    10
    *All other schedules required by 29 CFR 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable.
     




    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
     
    To the Participants and Administrator of
    CONMED Corporation Retirement Savings Plan
     
    Opinion on the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of CONMED Corporation Retirement Savings Plan (the Plan) as of December 31, 2025 and 2024, the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes to the financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2025 and 2024, and the changes in net assets available for benefits for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.
     
    Basis for Opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information
    The supplemental information in the accompanying schedule of assets (held at end of year) as of December 31, 2025 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is presented for the purpose of additional analysis and is not a required part of the financial statements but includes supplemental information required by the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. The supplemental information is the responsibility of the Plan's management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information in the accompanying schedule, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information in the accompanying schedule is fairly stated in all material respects in relation to the financial statements as a whole.


     
    /s/Insero & Co. CPAs, LLP 
     Certified Public Accountants 
     We have served as the Plan’s auditor since 2004.
     Rochester, New York 
     June 16, 2026 
     

    1



    CONMED Corporation
    Retirement Savings Plan
     
    Statements of Net Assets Available for Benefits
    December 31, 2025 and 2024
     20252024
    Assets  
      
    Investments, at Fair Value$379,879,535 $336,728,803 
    Notes Receivable from Participants4,820,514 5,049,944 
              Net Assets Available for Benefits$384,700,049 $341,778,747 
     
    The accompanying notes are an integral part of the financial statements.
     
    2


    CONMED Corporation
    Retirement Savings Plan
     
    Statement of Changes in Net Assets Available for Benefits
    Year Ended December 31, 2025
    Additions to net assets attributed to: 
         Net appreciation in fair value of investments$44,223,857 
         Interest and dividends13,529,600 
         Interest on notes receivable from participants393,655 
         Contributions: 
              Participants17,976,901 
              Employer7,275,075 
      
              Total additions83,399,088 
      
    Deductions from net assets attributed to: 
         Administrative expenses740,092 
         Distributions to participants39,737,694 
      
              Total deductions40,477,786 
      
              Net increase
    42,921,302 
    Net assets available for benefits at beginning of year341,778,747 
     
              Net assets available for benefits at end of year$384,700,049 
     
    The accompanying notes are an integral part of the financial statements.
     

    3


    CONMED Corporation
    Retirement Savings Plan
    Notes to Financial Statements
    December 31, 2025 and 2024
     

    Note 1 - Establishment and Description of Plan

        Effective January 1992, CONMED Corporation (the "Company") established the CONMED Corporation Retirement Savings Plan (the "Plan"). The Plan is a defined contribution plan covering all employees of the Company and its subsidiaries who meet the service requirements set forth in the Plan document. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 ("ERISA"). The following brief description of the Plan is provided for general information purposes only. Participants should refer to the Plan agreement for more complete information.
     
    Administration of the Plan
     
        The Company serves as Plan Administrator with full power, authority and responsibility to control and manage the operation and administration of the Plan.
     
    Contributions
     
        A participant can contribute 1 to 50 percent of his or her annual compensation, as defined, up to the maximum annual limitations as provided by the Internal Revenue Code (“IRC”). Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. Participants may also contribute amounts representing distributions from other qualified plans. The Plan includes an auto-enrollment provision whereby all newly eligible employees, defined as having completed 90 days of employment, are automatically enrolled in the Plan unless they affirmatively elect not to participate in the Plan. Automatically enrolled participants have their deferral rate set at 3% of eligible compensation and their contribution invested in a designated balanced fund until changed by the participant. The pre-tax contribution of an employee who is contributing less than 7% of the employee’s annual compensation, as defined in the plan document, automatically increases annually in 1% increments until the employee’s pre-tax contribution election reaches 7% of annual compensation, provided the employee has not elected to opt-out of the automatic increase feature. Employees with an initial enrollment date between July 2nd and December 31st in a given plan year that have not elected to opt-out of this election will not be subject to this annual increase until the following plan year.

        The Company matches 100% of each participant's contribution up to a maximum of 7% of participant compensation. The annual fixed Company match was capped at $7,000. Effective January 1, 2026, the Plan was amended to cap the annual fixed Company match at $10,000. The Company, in its sole discretion, may elect to make a discretionary matching contribution to the Plan. Forfeitures of terminated participants’ non-vested accounts are used to reduce employer contributions or to pay Plan expenses. Forfeitures reduced employer contributions by $1,792,124 in 2025. At December 31, 2025 and 2024, forfeited non-vested accounts totaled $312,001 and $141,228, respectively.
        
    Participant Accounts

        A participant can allocate their account among various investment funds. Each participant's account is credited with the participant's contribution, the Company's contribution, and an allocation of the earnings and losses for the participant's particular investment funds and charged with withdrawals and an allocation of administrative expenses. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.
        
    Vesting
     
        Each participant is immediately vested in his or her voluntary contributions plus earnings thereon. A participant vests at 20% per year of service and becomes fully vested in the remainder of his or her account upon the completion of five years of service.
     
    4


    Investment Options
     
        Participants are allowed to invest in a variety of investment choices as more fully described in the Plan literature. In addition, participants have access to a self-directed brokerage account. Through this account, a participant has access to investments including common stock, mutual funds, preferred stock, corporate bonds and money market funds. Participants may change their investment options on a daily basis.
     
    Notes Receivable from Participants
     
        A participant may obtain a loan between $500 and $50,000, limited to 50 percent of his or her vested account balance. A participant is eligible to have up to two general loans at one time and one home loan outstanding for a combined total of three loans outstanding at any one time. Each loan bears interest at prime plus 1 percent and is secured by the balance in the participant's account. Repayment is required over a period not to exceed five years or up to fifteen years where the loan is for the purchase of a primary residence. Loan repayments are allocated among the investment options consistent with the participant's contribution investment election.
     
    Payment of Benefits
     
        Participants or their beneficiaries are eligible to receive benefits under the Plan upon normal retirement, death, total and permanent disability or termination for any reason including those previously mentioned. The Plan also provides for withdrawals by participants prior to termination. Benefits are payable in accordance with the Plan agreement.
     
    Plan Termination
     
        While the Company anticipates and believes that the Plan will continue, it reserves the right to discontinue the Plan subject to the provisions of ERISA. In the event of Plan termination, participants will become 100 percent vested in their accounts.

    Note 2 - Significant Accounting Policies
     
    Basis of Accounting
     
        The accounts of the Plan are maintained on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
     
    Notes Receivable from Participants
     
        Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent notes receivable from participants are reclassified as distributions based upon the terms of the Plan document.
     
    Investment Valuation and Income Recognition
     
        Investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
     
        The Financial Accounting Standards Board ("FASB") guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. The FASB defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction. The framework requires an entity to maximize the use of observable inputs when measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:
     
    Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
     
    Level 2 - Inputs to the valuation methodology include:

    5


    •Quoted prices for similar assets or liabilities in active markets;
    •Quoted prices for identical or similar assets or liabilities in inactive markets;
    •Inputs other than quoted prices that are observable for the asset or liability;
    •Inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.

        If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.
     
    Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
     
        The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

        Following is a description of the valuation methodologies used for investments measured at fair value. There have been no changes in the methodologies used at December 31, 2025 and 2024.
     
    Mutual Funds
     
        These investments are public investment vehicles valued using the Net Asset Value (“NAV”) provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in an active market and classified within level 1 of the valuation hierarchy.

    Self-directed Brokerage Account
     
        The self-directed brokerage account consists primarily of common stock, mutual funds, preferred stock, corporate bonds and money market funds. Common stock, preferred stock and corporate bonds are valued at the closing price reported on the investments' respective stock exchange or active market. Mutual funds and money market funds are valued using NAV. All investments are classified within level 1 of the valuation hierarchy.

    Common Stock
     
        Common stock is valued at the closing price reported on the common stock’s respective stock exchange and is classified within level 1 of the valuation hierarchy.

    Money Market Funds
     
        These investments are public investment vehicles valued using NAV. The money market funds are classified within level 1 of the valuation hierarchy.
     
    Collective Investment Trusts
     
        Collective investment trusts (“CITs”) are valued at fair value when the trust’s NAV is published on a public stock market and classified within Level 2 of the valuation hierarchy. When the NAV is not published, the CIT’s unpublished NAV is used as a practical expedient to estimate fair value and is obtained from information provided by the investment advisor using the audited financial statements of the collective investment trusts at year end. Under the practical expedient, the investment is not classified in the valuation hierarchy.
     
        The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

    6


        The following table sets forth, by level within the fair value hierarchy, the Plan's investments, at fair value:
      
     Investments, at Fair Value as of
    December 31, 2025
     Level 1Level 2Total
    Mutual Funds$298,713,143 $— $298,713,143 
    Self-directed Brokerage Account16,174,892 — 16,174,892 
    Common Stock2,491,300 — 2,491,300 
    Money Market Funds7,644,077 — 7,644,077 
    Collective Investment Trusts— 36,842,007 36,842,007 
    Investments measured at fair value325,023,412 36,842,007 361,865,419 
    Investments measured at NAV as a practical expedient (a)
     18,014,116 
    Total investments, at fair value $379,879,535 
     
     Investments, at Fair Value as of
    December 31, 2024
     Level 1
    Level 2
    Total
    Mutual Funds$303,974,251 $— $303,974,251 
    Self-directed Brokerage Account12,329,390 — 12,329,390 
    Common Stock4,886,191 — 4,886,191 
    Money Market Funds7,894,825 — 7,894,825 
    Collective Investment Trusts
    — — — 
    Investments measured at fair value329,084,657 — 329,084,657 
    Investments measured at NAV as a practical expedient (a)
     7,644,146 
    Total investments, at fair value $336,728,803 
     
        (a) In accordance with Subtopic 820-10, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Statements of Net Assets Available for Benefits.
     
        Purchases and sales of securities are recorded on a trade-date basis. Dividends are recorded on the ex-dividend date. Interest is recorded on the accrual basis. Net appreciation includes the Plan's gains and losses on investments bought and sold as well as held during the year.
     
    Contributions
     
        Participant contributions and matching employer contributions are recorded in the period during which the Company makes payroll deductions from the participants’ earnings.
     
    Administrative Expenses
     
        The Plan’s administrative expenses are paid by either the Plan or the Plan’s Sponsor as defined in the Plan document.
     
    Payment of Benefits
     
        Benefit payments to participants are recorded upon distribution.
     
    Use of Estimates
     
        The preparation of the Plan’s financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets,
    7


    liabilities, and changes therein, and disclosures of contingent assets and liabilities. The Company is not aware of any specific events or circumstance that would require disclosure or an update to estimates or judgments or a revision of the carrying value of the Plan's assets or liabilities through June 16, 2026. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.
     
    Risks and Uncertainties
     
        The Plan invests in various investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit risks. Market risks include global events which could impact the value of investment securities, such as inflation, a pandemic or international conflict. Due to the level of risk associated with these investments, it is at least reasonably possible that changes in their values will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the Statements of Net Assets Available for Benefits.

    Note 3 - Income Tax Status

        The trust established under the Plan to hold the Plan’s assets is qualified pursuant to the appropriate section of the IRC, and, accordingly, the trust’s net investment income is exempt from income taxes. The Plan has obtained a favorable tax determination letter, dated August 2, 2017, from the Internal Revenue Service (“IRS”). The Plan Administrator and the Plan’s tax counsel believe that the Plan, as amended, is designed, and is currently being operated, in compliance with the applicable requirements of the IRC.
        
        Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2025, there are no uncertain positions taken, or expected to be taken, that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

    Note 4 - Transactions with Parties-in-Interest

        As of December 31, 2025 and 2024, the Plan held certain securities issued by the Company as follows:
     
     December 31, 2025December 31, 2024
    Number
    of
    Shares
    Fair
    Value
    Number
    of
    Shares
     Fair
    Value
    CONMED Corporation    
         Common Stock61,362 $2,491,300 71,394 $4,886,191 

        In addition, certain assets of the Plan are invested in funds managed by Fidelity Management Trust Company ("Fidelity"). Fidelity is the trustee of the Plan and, therefore, is considered to be a party-in-interest. Notes receivable from participants also qualify as party-in-interest transactions.


    8


    CONMED Corporation
    Retirement Savings Plan
    Schedule H, line 4i - Schedule of Assets (Held at End of Year)
    December 31, 2025
    EIN: 16-0977505
    Plan Number: 005
     Current
    Identity of Issue/Description of InvestmentValue
      
    Fidelity 500 Index Fund**$60,265,499 
    Fidelity Freedom 2045 Fund - Class K6**27,401,429 
    Fidelity Freedom 2040 Fund - Class K6**26,565,892 
    Fidelity Contrafund - Class K**26,487,069 
    Fidelity Freedom 2035 Fund - Class K6**25,668,275 
    Fidelity Freedom 2050 Fund - Class K6**22,534,823 
    Fidelity Freedom 2030 Fund - Class K6**19,522,532 
    Fidelity Freedom 2055 Fund - Class K6**17,398,038 
    Janus Henderson Enterprise Collective Fund Class III16,589,884 
    Participant - Directed Brokerage Link Account16,174,892 
    Fidelity Freedom 2025 Fund - Class K6**14,765,811 
    Fidelity Freedom 2060 Fund - Class K6**13,151,058 
    John Hancock Disciplined Value Mid Cap Trust Class B510,588,966 
    Putnam Large Cap Value Trust IA10,562,568 
    Fidelity Government Money Market Fund - Class K6**7,642,655 
    Fidelity Diversified International Fund - Class K**7,540,974 
    John Hancock Core Plus Fixed Income Trust Class I27,105,286 
    Fidelity Global ex U.S. Index Fund**6,829,533 
    Fidelity Managed Income Portfolio - Class 1**6,745,058 
    Fidelity Freedom 2020 Fund - Class K6**5,486,841 
    Fidelity U.S. Bond Index Fund**5,405,252 
    Fidelity Extended Market Index Fund**5,093,126 
    Fidelity Freedom 2065 Fund - Class K6**4,154,509 
    Fidelity Emerging Markets Fund - Class K**3,481,110 
    Franklin Small Cap Value GG Trust CIT Class R2,557,871 
    CONMED Corporation Common Stock **2,491,300 
    JP Morgan U.S. Small Company Fund Class R62,483,790 
    PIMCO Income Fund Institutional Class1,762,825 
    Fidelity Freedom Retirement Fund - Class K6**948,184 
    Fidelity Freedom 2015 Fund - Class K6**946,390 
    Putnam Stable Value Fund706,490 
    Fidelity Freedom 2010 Fund - Class K6**579,645 
    Fidelity Freedom 2070 Fund - Class K6**160,486 
    Invesco Discovery Fund Class R680,052 
    Interest Bearing Cash Accounts1,422 
    Notes receivable from participants, interest rates from
    4.25% to 9.50% and maturities from 2026 to 2040**
    4,820,514 
     $384,700,049 
    ** Denotes party-in-interest
    9



    SIGNATURES
     
        Pursuant to the requirements of the Securities Exchange Act of 1934, the Plan Administrator has duly caused this Annual Report to be signed by the undersigned hereunto duly authorized.
     
     CONMED CORPORATION
     Retirement Savings Plan
      
     By:/s/ Patrick J. Beyer
     Name:Patrick J. Beyer
     Title:President, Chief Executive Officer
    Interim Principal Financial Officer
     
    Date: June 16, 2026
     

    10
    Get the next $CNMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    3/17/2026$39.00Overweight → Neutral
    Piper Sandler
    6/12/2025Buy → Hold
    Needham
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    More analyst ratings

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bronson David M. converted options into 668 shares, increasing direct ownership by 4% to 17,909 units (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    6/3/26 4:22:33 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Council Laverne H converted options into 668 shares, increasing direct ownership by 17% to 4,716 units (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    6/3/26 4:18:56 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Kelderman Kim

    4 - CONMED Corp (0000816956) (Issuer)

    6/3/26 4:17:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    SEC Filings

    View All

    CONMED Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - CONMED Corp (0000816956) (Filer)

    6/17/26 4:49:40 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 11-K filed by CONMED Corporation

    11-K - CONMED Corp (0000816956) (Filer)

    6/16/26 4:30:58 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - CONMED Corp (0000816956) (Filer)

    6/4/26 7:30:38 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

    CONMED Corporation (NYSE:CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer ("CFO"), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. "We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "John brings deep healthcare and medical technology experience, an extensive history of public company leadership, and a proven track record of leading global finance organizations and supporting complex strategic initiatives. His combination of industry experti

    6/17/26 4:35:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors ("Board"), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors. "My fellow directors and I are delighted to welcome Celine Martin and Jeff Mirviss to the Board, both highly accomplished leaders with extensive experience developed at two of the largest companies in the healt

    5/20/26 8:30:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces First Quarter 2026 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from the exit of certain GI products. International revenue increased 4.7% year-over-year as reported and 1.0% in constant currency. International sales growth was impacted by a $0.3 million decrease in sales from the exit of c

    4/29/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/14/24 3:37:54 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/10/24 5:29:04 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/8/24 4:20:48 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CONMED downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded CONMED from Overweight to Neutral and set a new price target of $39.00

    3/17/26 7:55:41 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Needham

    Needham downgraded CONMED from Buy to Hold

    6/12/25 7:52:09 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Stifel with a new price target

    Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

    4/28/25 8:32:52 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    View All

    CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

    CONMED Corporation (NYSE:CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer ("CFO"), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. "We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "John brings deep healthcare and medical technology experience, an extensive history of public company leadership, and a proven track record of leading global finance organizations and supporting complex strategic initiatives. His combination of industry experti

    6/17/26 4:35:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors ("Board"), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors. "My fellow directors and I are delighted to welcome Celine Martin and Jeff Mirviss to the Board, both highly accomplished leaders with extensive experience developed at two of the largest companies in the healt

    5/20/26 8:30:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

    5/21/25 7:03:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Financials

    Live finance-specific insights

    View All

    CONMED Corporation Announces First Quarter 2026 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from the exit of certain GI products. International revenue increased 4.7% year-over-year as reported and 1.0% in constant currency. International sales growth was impacted by a $0.3 million decrease in sales from the exit of c

    4/29/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

    4/2/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024. Adjusted diluted net earnings per share(1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2

    1/28/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/13/24 4:22:22 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/12/24 12:53:28 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    2/13/24 5:02:29 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care